Tumor shrinkage with Combination of Alectinib and Trastuzumab in a Patient with ALK-Rearranged Non-small Cell Lung Cancer Harboring HER2-amplification as an Acquired Resistance Mechanism to ALK Inhibitor Therapy
HER2 amplification is an acquired resistance mechanism in ALK-rearranged non-small cell lung cancer. READ ARTICLE
Clinical Lung Cancer DOI: 10.1016/j.cllc.2021.06.012
Authors: David Chun, Cheong Tsui, Dara Aisner, Hala Nijmeh, Liming Bao, Alexander Menter and Ross Camidge